Publications

Oncogene

The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR.

16-03-2000

International journal of radiation oncology, biology, physics

A treatment planning method to correct dose distributions distorted by setup verification fields.

15-03-2000

The cancer journal from Scientific American

Translational research offers individually tailored treatments for cancer patients.

04-03-2000

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

The bactericidal/permeability-increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation.

01-03-2000

Drug metabolism and disposition: the biological fate of chemicals

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

01-03-2000

Journal of cell science

Formation of hemidesmosome-like structures in the absence of ligand binding by the (alpha)6(beta)4 integrin requires binding of HD1/plectin to the cytoplasmic domain of the (beta)4 integrin subunit.

01-03-2000

Cancer chemotherapy and pharmacology

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.

09-02-2000

The Journal of clinical investigation

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

01-02-2000

Fresenius' journal of analytical chemistry

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.

01-02-2000

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.

01-02-2000

American journal of human genetics

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

01-02-2000

International journal of pharmaceutics

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

25-01-2000

Journal of the National Cancer Institute

Physical activity and breast cancer risk in women aged 20-54 years.

19-01-2000

The Journal of cell biology

Induction of cell scattering by expression of beta1 integrins in beta1-deficient epithelial cells requires activation of members of the rho family of GTPases and downregulation of cadherin and catenin function.

13-12-1999

Journal of cell science

Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status.

01-12-1999

The EMBO journal

The modified base J is the target for a novel DNA-binding protein in kinetoplastid protozoans.

15-11-1999

Investigational new drugs

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

11-11-1999

The Journal of clinical investigation

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

01-11-1999

Anti-cancer drugs

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

01-11-1999

International journal of radiation oncology, biology, physics

Dose-wall histograms and normalized dose-surface histograms for the rectum: a new method to analyze the dose distribution over the rectum in conformal radiotherapy.

01-11-1999

Journal of cell science

Partial rescue of epithelial phenotype in integrin beta4 null mice by a keratin-5 promoter driven human integrin beta4 transgene.

01-11-1999

The Journal of experimental medicine

Selective expansion of cross-reactive CD8(+) memory T cells by viral variants.

01-11-1999

Mechanisms of development

In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3.

01-11-1999

International journal of radiation oncology, biology, physics

Comparison of prostate cancer treatment in two institutions: a quality control study.

01-11-1999

Journal of cancer research and clinical oncology

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.

01-11-1999

Analytical biochemistry

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

01-11-1999

Biochimica et biophysica acta

CDK-independent activities of D type cyclins.

29-10-1999

Oncogene

Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression.

28-10-1999

The Journal of cell biology

Binding of integrin alpha6beta4 to plectin prevents plectin association with F-actin but does not interfere with intermediate filament binding.

18-10-1999

Genes & development

Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.

15-10-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

01-10-1999

Proceedings of the National Academy of Sciences of the United States of America

Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.

28-09-1999

Oncogene

Developmental defects and tumor predisposition in Rb mutant mice.

20-09-1999

Nederlands tijdschrift voor geneeskunde

[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].

11-09-1999

Cancer research

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

01-09-1999

British journal of cancer

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

01-09-1999

British journal of cancer

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses.

01-09-1999

Proceedings of the National Academy of Sciences of the United States of America

Recycling MHC class I molecules and endosomal peptide loading.

31-08-1999

Cancer chemotherapy and pharmacology

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.

14-08-1999

The EMBO journal

Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1

02-08-1999

Nature cell biology

Rac regulates phosphorylation of the myosin-II heavy chain, actinomyosin disassembly and cell spreading.

01-08-1999

European journal of drug metabolism and pharmacokinetics

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

21-07-1999

Cellular immunology

Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells.

10-07-1999

Immunity

Pre-TCR signaling and inactivation of p53 induces crucial cell survival pathways in pre-T cells.

01-07-1999

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

In vivo dosimetry during conformal radiotherapy: requirements for and findings of a routine procedure.

01-07-1999

Pharmacological research

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

01-07-1999

British journal of cancer

Oral topotecan: bioavailablity and effect of food co-administration.

01-07-1999

Patient education and counseling

Psychosocial factors in the etiology of breast cancer: review of a popular link.

01-07-1999

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

01-06-1999

The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR.

A treatment planning method to correct dose distributions distorted by setup verification fields.

Translational research offers individually tailored treatments for cancer patients.

The bactericidal/permeability-increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation.

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

Formation of hemidesmosome-like structures in the absence of ligand binding by the (alpha)6(beta)4 integrin requires binding of HD1/plectin to the cytoplasmic domain of the (beta)4 integrin subunit.

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

Physical activity and breast cancer risk in women aged 20-54 years.

Induction of cell scattering by expression of beta1 integrins in beta1-deficient epithelial cells requires activation of members of the rho family of GTPases and downregulation of cadherin and catenin function.

Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status.

The modified base J is the target for a novel DNA-binding protein in kinetoplastid protozoans.

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

Dose-wall histograms and normalized dose-surface histograms for the rectum: a new method to analyze the dose distribution over the rectum in conformal radiotherapy.

Partial rescue of epithelial phenotype in integrin beta4 null mice by a keratin-5 promoter driven human integrin beta4 transgene.

Selective expansion of cross-reactive CD8(+) memory T cells by viral variants.

In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3.

Comparison of prostate cancer treatment in two institutions: a quality control study.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

CDK-independent activities of D type cyclins.

Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression.

Binding of integrin alpha6beta4 to plectin prevents plectin association with F-actin but does not interfere with intermediate filament binding.

Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.

Developmental defects and tumor predisposition in Rb mutant mice.

[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses.

Recycling MHC class I molecules and endosomal peptide loading.

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.

Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1

Rac regulates phosphorylation of the myosin-II heavy chain, actinomyosin disassembly and cell spreading.

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells.

Pre-TCR signaling and inactivation of p53 induces crucial cell survival pathways in pre-T cells.

In vivo dosimetry during conformal radiotherapy: requirements for and findings of a routine procedure.

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

Oral topotecan: bioavailablity and effect of food co-administration.

Psychosocial factors in the etiology of breast cancer: review of a popular link.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

This site uses cookies